Results from a preclinical study of Variation's influenza vaccine to be presented at ICAAC meeting

Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today announced that it plans to present positive results from a preclinical study of the company’s proprietary influenza vaccine at the 49^th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), being held at the Moscone Convention Center in San Francisco, California.

Dr. David E. Anderson, Vice President, Immunology and co-founder of Variation, will present the poster, entitled, “Efficacy and Broadly Reactive Immunity Directed Against Seasonal and Pandemic Strains of Influenza Using Variosite^TM Technology,” on Sunday, September 13 from 11:15 am – 1:15 pm in Hall B of the Moscone Center. The presentation will be made available on the Variation website, www.variationbiotech.com on Monday, September 14.

“These data demonstrate the potential of our influenza vaccine and establish our Variosite^TM technology as a novel means of developing vaccines that induce broadly reactive immunity to protect against infection by variable pathogens,” said Dr. Anderson. “We are extremely proud to have been selected to present these data at the 49^th Annual ICAAC meeting, and are thankful to the meeting organizers for this opportunity.”